BET Proteins as Targets for Anticancer Treatment
The DOI matches its Crossref record; 140 of the 140 references it cites were found in a registry or an index.
Abstract
Bromodomain and extraterminal domain (BET) proteins are epigenetic readers that regulate gene expression and are involved in cancer pathogenesis. Over the last years, several BET inhibitors have been developed and clinically tested. Results from the first clinical trials show limited single-agent activity in a small subset of patients with hematologic malignancies and in NUT carcinoma. Adverse events have been observed and may limit treatment compliance. Here, we review the preclinical rationale for targeting BET proteins in cancer and the preliminary results from clinical trials, and outline future directions for the use of BET inhibitors as antitumor agents. Significance: BET inhibitors represent a new class of anticancer agents. Results from the first clinical trials confirm the antitumor potential of BET inhibitors, but their efficacy as single agents seems to be limited. Based on preclinical data, combination therapies with other anticancer agents and the development of a new generation of compounds may open new possibilities for targeting BET proteins as effective anticancer strategies. Cancer Discov; 8(1); 24–36. ©2017 AACR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The epigenetic reader bromodomain-containing protein 4 (BRD4), an acetylated histone-binding protein involved in oncogenesis, is recruited to superenhancers adjacent to SASP genes in OIS103.”
From Cellular senescence in ageing: from mechanisms to therapeutic opportunities (2021) · cites this paper as [103]
Citations
Cites
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262 · cited 1×
“More importantly, the displacement of the BRD4 oncoprotein from chromatin using the BET inhibitor JQ1 has antiproliferative activity with squamous differentiation in BRD4-dependent cell lines and patient-derived xenograft models (27).”
MethodMaster Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes
Whyte, W. A., Orlando, D. A., Hnisz, D., Abraham, B. J., Lin, C. Y., Kagey, M. H., Rahl, P. B., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.035 · Cited by 4,143
Super-enhancers in the control of cell identity and disease
Hnisz, D., Abraham, B. J., Lee, T. I., Lau, A., Saint-André, V., Sigova, A. A., Hoke, H. A., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.09.053 · Cited by 3,662
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.036 · Cited by 2,961
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Delmore, J. E., Issa, G. C., Lemieux, M. E., Rahl, P. B., Shi, J., Jacobs, H. M., Kastritis, E., Gilpatrick, T., Paranal, R. M., Qi, J., et al. (2011) · Cell · doi:10.1016/j.cell.2011.08.017 · Cited by 2,813 · cited 1×
“Overexpression of BRD2/BRD4 genes also occurs in human cancers (23, 24).”
BackgroundSakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., & Deshaies, R. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141230798 · Cited by 2,609
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Zuber, J., Shi, J., Wang, E., Rappaport, A. R., Herrmann, H., Sison, E. A., Magoon, D., Qi, J., Blatt, K., Wunderlich, M., et al. (2011) · Nature · doi:10.1038/nature10334 · Cited by 1,870
Phthalimide conjugation as a strategy for in vivo target protein degradation
Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760
Suppression of inflammation by a synthetic histone mimic
Nicodeme, E., Jeffrey, K. L., Schaefer, U., Beinke, S., Dewell, S., Chung, C.-W., Chandwani, R., Marazzi, I., Wilson, P., Coste, H., et al. (2010) · Nature · doi:10.1038/nature09589 · Cited by 1,563
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
Dawson, M. A., Prinjha, R. K., Dittmann, A., Giotopoulos, G., Bantscheff, M., Chan, W.-I., Robson, S. C., Chung, C.-W., Hopf, C., Savitski, M. M., et al. (2011) · Nature · doi:10.1038/nature10509 · Cited by 1,503
Jang, M. K., Mochizuki, K., Zhou, M., Jeong, H.-S., Brady, J. N., & Ozato, K. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.06.027 · Cited by 1,291
Structural basis of PROTAC cooperative recognition for selective protein degradation
Gadd, M. S., Testa, A., Lucas, X., Chan, K.-H., Chen, W., Lamont, D. J., Zengerle, M., & Ciulli, A. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2329 · Cited by 1,242
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Lu, J., Qian, Y., Altieri, M., Dong, H., Wang, J., Raina, K., Hines, J., Winkler, J. D., Crew, A. P., Coleman, K., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.05.009 · Cited by 1,140
Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4
Zengerle, M., Chan, K.-H., & Ciulli, A. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00216 · Cited by 1,056
Prospects for combining targeted and conventional cancer therapy with immunotherapy
Gotwals, P., Cameron, S., Cipolletta, D., Cremasco, V., Crystal, A., Hewes, B., Mueller, B., Quaratino, S., Sabatos-Peyton, C., Petruzzelli, L., et al. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.17 · Cited by 953
The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition
Shi, J., & Vakoc, C. R. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.05.016 · Cited by 878
PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
Raina, K., Lu, J., Qian, Y., Altieri, M., Gordon, D., Rossi, A. M. K., Wang, J., Chen, X., Dong, H., Siu, K., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521738113 · Cited by 852
Chapuy, B., McKeown, M. R., Lin, C. Y., Monti, S., Roemer, M. G. M., Qi, J., Rahl, P. B., Sun, H. H., Yeda, K. T., Doench, J. G., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.11.003 · Cited by 735
BET domain co-regulators in obesity, inflammation and cancer
Belkina, A. C., & Denis, G. V. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3256 · Cited by 711
Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition
Puissant, A., Frumm, S. M., Alexe, G., Bassil, C. F., Qi, J., Chanthery, Y. H., Nekritz, E. A., Zeid, R., Gustafson, W. C., Greninger, P., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0418 · Cited by 637 · cited 1×
“Signatures of exposure to BET inhibitors are relatively similar among different tumor types (31, 34, 35), but specific changes predominate in different cellular contexts in which BET inhibitors directly affect key tissue- or cancer-specific genes, mainly transcription factors (1, 4, 8, 28, 29, 31, 36–42).”
BackgroundResponse and resistance to BET bromodomain inhibitors in triple-negative breast cancer
Shu, S., Lin, C. Y., He, H. H., Witwicki, R. M., Tabassum, D. P., Roberts, J. M., Janiszewska, M., Jin Huh, S., Liang, Y., Ryan, J., et al. (2016) · Nature · doi:10.1038/nature16508 · Cited by 632 · cited 2×
“Increased WNT signaling with β-catenin–mediated MYC expression in AML (88, 89), activation of the Hedgehog pathway with GLI2-mediated MYC expression in pancreatic cancer (90), hyperphosphorylation of BRD4 that leads to a bromodomain-independent binding to MED1 in triple-negative breast cancer (42), kinome reprogrammin…”
BackgroundBET inhibitor resistance emerges from leukaemia stem cells
Fong, C. Y., Gilan, O., Lam, E. Y. N., Rubin, A. F., Ftouni, S., Tyler, D., Stanley, K., Sinha, D., Yeh, P., Morison, J., et al. (2015) · Nature · doi:10.1038/nature14888 · Cited by 545 · cited 10×
“Combination partners that have shown synergism with BET inhibitors in preclinical tumor models Classes Second compound Experimental disease model Small molecules ALK inhibitors Lymphoma ( 31 ) BTK inhibitors Lymphoma ( 28, 31, 35, 36 , 100, 101, 114 ) CDK inhibitors Lymphoma ( 100, 101 ), osteosarcoma ( 51 ) BCL2/MCL1…”
BackgroundInfluentialTranscriptional plasticity promotes primary and acquired resistance to BET inhibition
Rathert, P., Roth, M., Neumann, T., Muerdter, F., Roe, J.-S., Muhar, M., Deswal, S., Cerny-Reiterer, S., Peter, B., Jude, J., et al. (2015) · Nature · doi:10.1038/nature14898 · Cited by 499 · cited 9×
“Combination partners that have shown synergism with BET inhibitors in preclinical tumor models Classes Second compound Experimental disease model Small molecules ALK inhibitors Lymphoma ( 31 ) BTK inhibitors Lymphoma ( 28, 31, 35, 36 , 100, 101, 114 ) CDK inhibitors Lymphoma ( 100, 101 ), osteosarcoma ( 51 ) BCL2/MCL1…”
BackgroundInfluentialShi, J., Wang, Y., Zeng, L., Wu, Y., Deng, J., Zhang, Q., Lin, Y., Li, J., Kang, T., Tao, M., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.028 · Cited by 477
RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain
Picaud, S., Wells, C., Felletar, I., Brotherton, D., Martin, S., Savitsky, P., Diez-Dacal, B., Philpott, M., Bountra, C., Lingard, H., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1310658110 · Cited by 468
Winter, G. E., Mayer, A., Buckley, D. L., Erb, M. A., Roderick, J. E., Vittori, S., Reyes, J. M., di Iulio, J., Souza, A., Ott, C. J., et al. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.06.004 · Cited by 465
Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance
Marcotte, R., Sayad, A., Brown, K. R., Sanchez-Garcia, F., Reimand, J., Haider, M., Virtanen, C., Bradner, J. E., Bader, G. D., Mills, G. B., et al. (2016) · Cell · doi:10.1016/j.cell.2015.11.062 · Cited by 451 · cited 2×
“Overexpression of BRD2/BRD4 genes also occurs in human cancers (23, 24).”
BackgroundFrench, C. A., Ramirez, C. L., Kolmakova, J., Hickman, T. T., Cameron, M. J., Thyne, M. E., Kutok, J. L., Toretsky, J. A., Tadavarthy, A. K., Kees, U. R., et al. (2008) · Oncogene · doi:10.1038/sj.onc.1210852 · Cited by 441 · cited 4×
“The translocation creates an in-frame BRD4–NUT oncogene driven by the BRD4 promoter that is considered a major pathogenetic driver of cellular transformation (26).”
BackgroundInfluentialDiagnosis of NUT Midline Carcinoma Using a NUT-specific Monoclonal Antibody
Haack, H., Johnson, L. A., Fry, C. J., Crosby, K., Polakiewicz, R. D., Stelow, E. B., Hong, S.-M., Schwartz, B. E., Cameron, M. J., Rubin, M. A., et al. (2009) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e318198d666 · Cited by 435 · cited 1×
“In addition, although FISH confirmation of the chromosomal translocation is not necessary for diagnostic purposes (68), it should be implemented in clinical trials to assess whether the partner gene (BRD4 vs.”
BackgroundBromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
Berthon, C., Raffoux, E., Thomas, X., Vey, N., Gomez-Roca, C., Yee, K., Taussig, D. C., Rezai, K., Roumier, C., Herait, P., et al. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(15)00247-1 · Cited by 420 · cited 1×
“No correlation was found between somatic mutations in 42 genes (including NPM1, IDH2, FLT3, EV11, and MLL) and response to OTX015 comparing 5 responders versus 28 nonresponders (60).”
BackgroundAmorim, S., Stathis, A., Gleeson, M., Iyengar, S., Magarotto, V., Leleu, X., Morschhauser, F., Karlin, L., Broussais, F., Rezai, K., et al. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(16)00021-1 · Cited by 417 · cited 2×
“The schedule consisted of 80 mg once daily, administered orally in 3-week cycles, based on the dose that was already tested and declared safe in the phase I hematologic study (61).”
BackgroundMethodSelf-citationBRD4 Connects Enhancer Remodeling to Senescence Immune Surveillance
Tasdemir, N., Banito, A., Roe, J.-S., Alonso-Curbelo, D., Camiolo, M., Tschaharganeh, D. F., Huang, C.-H., Aksoy, O., Bolden, J. E., Chen, C.-C., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0217 · Cited by 415 · cited 1×
“Finally, a tumor-suppressor role for BET proteins has also been reported in which their inhibition would result in a reduced immune surveillance (86) and reduced capacity of healthy cells to counteract the neoplastic transformation process (87).”
BackgroundBrd4 and JMJD6-Associated Anti-Pause Enhancers in Regulation of Transcriptional Pause Release
Liu, W., Ma, Q., Wong, K., Li, W., Ohgi, K., Zhang, J., Aggarwal, A. K., & Rosenfeld, M. G. (2013) · Cell · doi:10.1016/j.cell.2013.10.056 · Cited by 406
Mazur, P. K., Herner, A., Mello, S. S., Wirth, M., Hausmann, S., Sánchez-Rivera, F. J., Lofgren, S. M., Kuschma, T., Hahn, S. A., Vangala, D., et al. (2015) · Nature Medicine · doi:10.1038/nm.3952 · Cited by 397
Targeting Epigenetic Readers in Cancer
Dawson, M. A., Kouzarides, T., & Huntly, B. J. P. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1112635 · Cited by 397
Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcription
Bisgrove, D. A., Mahmoudi, T., Henklein, P., & Verdin, E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705053104 · Cited by 387
Stathis, A., Zucca, E., Bekradda, M., Gomez-Roca, C., Delord, J.-P., de La Motte Rouge, T., Uro-Coste, E., de Braud, F., Pelosi, G., & French, C. A. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1335 · Cited by 378 · cited 4×
“The duration of response was 13 cycles in 1 patient and 3 cycles in the second patient (64).”
BackgroundInfluentialSelf-citationBET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia
Ott, C. J., Kopp, N., Bird, L., Paranal, R. M., Qi, J., Bowman, T., Rodig, S. J., Kung, A. L., Bradner, J. E., & Weinstock, D. M. (2012) · Blood · doi:10.1182/blood-2012-02-413021 · Cited by 374
Zhou, B., Hu, J., Xu, F., Chen, Z., Bai, L., Fernandez-Salas, E., Lin, M., Liu, L., Yang, C.-Y., Zhao, Y., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01816 · Cited by 358
BET Bromodomain Inhibition of MYC -Amplified Medulloblastoma
Bandopadhayay, P., Bergthold, G., Nguyen, B., Schubert, S., Gholamin, S., Tang, Y., Bolin, S., Schumacher, S. E., Zeid, R., Masoud, S., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2281 · Cited by 352
Phospho Switch Triggers Brd4 Chromatin Binding and Activator Recruitment for Gene-Specific Targeting
Wu, S.-Y., Lee, A.-Y., Lai, H.-T., Zhang, H., & Chiang, C.-M. (2013) · Molecular Cell · doi:10.1016/j.molcel.2012.12.006 · Cited by 347
Dual kinase-bromodomain inhibitors for rationally designed polypharmacology
Ciceri, P., Müller, S., O'Mahony, A., Fedorov, O., Filippakopoulos, P., Hunt, J. P., Lasater, E. A., Pallares, G., Picaud, S., Wells, C., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1471 · Cited by 338
Roe, J.-S., Mercan, F., Rivera, K., Pappin, D. J., & Vakoc, C. R. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.04.011 · Cited by 337
Lockwood, W. W., Zejnullahu, K., Bradner, J. E., & Varmus, H. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1216363109 · Cited by 327
Houzelstein, D., Bullock, S. L., Lynch, D. E., Grigorieva, E. F., Wilson, V. A., & Beddington, R. S. P. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.11.3794-3802.2002 · Cited by 318 · cited 1×
“The complete lack of either BRD2 or BRD4 is lethal (12–15) and, in general, low BET protein level is associated with reduced cell growth (12, 13).”
BackgroundHogg, S. J., Vervoort, S. J., Deswal, S., Ott, C. J., Li, J., Cluse, L. A., Beavis, P. A., Darcy, P. K., Martin, B. P., Spencer, A., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.02.011 · Cited by 308
Drug Discovery Targeting Bromodomain-Containing Protein 4
Liu, Z., Wang, P., Chen, H., Wold, E. A., Tian, B., Brasier, A. R., & Zhou, J. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01761 · Cited by 303
Boi, M., Gaudio, E., Bonetti, P., Kwee, I., Bernasconi, E., Tarantelli, C., Rinaldi, A., Testoni, M., Cascione, L., Ponzoni, M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1561 · Cited by 284 · cited 2×
“Results from the OTX015 phase I trial might suggest an association between the non–germinal center B cell–like phenotype and treatment response, in line with preclinical data reporting strong capacity of BET inhibitors to downregulate the NF-kB, TLR, and JAK/STAT3 signaling pathways (28, 36), crucial in this subtype o…”
BackgroundResultSelf-citationSuper-Enhancer-Mediated RNA Processing Revealed by Integrative MicroRNA Network Analysis
Suzuki, H. I., Young, R. A., & Sharp, P. A. (2017) · Cell · doi:10.1016/j.cell.2017.02.015 · Cited by 284
BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells
Coudé, M.-M., Braun, T., Berrou, J., Dupont, M., Bertrand, S., Masse, A., Raffoux, E., Itzykson, R., Delord, M., Riveiro, M. E., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4131 · Cited by 274
Stuhlmiller, T. J., Miller, S. M., Zawistowski, J. S., Nakamura, K., Beltran, A. S., Duncan, J. S., Angus, S. P., Collins, K. A. L., Granger, D. A., Reuther, R. A., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.037 · Cited by 270
Brd4 maintains constitutively active NF-κB in cancer cells by binding to acetylated RelA
Zou, Z., Huang, B., Wu, X., Zhang, H., Qi, J., Bradner, J., Nair, S., & Chen, L.-F. (2014) · Oncogene · doi:10.1038/onc.2013.179 · Cited by 259
BET bromodomain inhibition as a novel strategy for reactivation of HIV-1
Banerjee, C., Archin, N., Michaels, D., Belkina, A. C., Denis, G. V., Bradner, J., Sebastiani, P., Margolis, D. M., & Montano, M. (2012) · Journal of Leukocyte Biology · doi:10.1189/jlb.0312165 · Cited by 256 · cited 1×
“Although this can be therapeutically exploited to eliminate latent viral infections (76, 77, 82), it advises for a close monitoring of patients with cancer receiving BET inhibitors for reactivation of viral infections.”
BackgroundReactivation of Latent HIV-1 by Inhibition of BRD4
Zhu, J., Gaiha, G. D., John, S. P., Pertel, T., Chin, C. R., Gao, G., Qu, H., Walker, B. D., Elledge, S. J., & Brass, A. L. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.09.008 · Cited by 244 · cited 1×
“Although this can be therapeutically exploited to eliminate latent viral infections (76, 77, 82), it advises for a close monitoring of patients with cancer receiving BET inhibitors for reactivation of viral infections.”
BackgroundNSD3–NUT Fusion Oncoprotein in NUT Midline Carcinoma: Implications for a Novel Oncogenic Mechanism
French, C. A., Rahman, S., Walsh, E. M., Kühnle, S., Grayson, A. R., Lemieux, M. E., Grunfeld, N., Rubin, B. P., Antonescu, C. R., Zhang, S., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0014 · Cited by 243 · cited 1×
“1, or less commonly to other genes, including BRD3 and NSD3BRD (25, 26).”
BackgroundFunctional genomics identifies therapeutic targets for MYC-driven cancer
Toyoshima, M., Howie, H. L., Imakura, M., Walsh, R. M., Annis, J. E., Chang, A. N., Frazier, J., Chau, B. N., Loboda, A., Linsley, P. S., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121119109 · Cited by 242
Repression of BET activity sensitizes homologous recombination–proficient cancers to PARP inhibition
Yang, L., Zhang, Y., Shan, W., Hu, Z., Yuan, J., Pi, J., Wang, Y., Fan, L., Tang, Z., Li, C., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal1645 · Cited by 242
BET protein Brd4 activates transcription in neurons and BET inhibitor Jq1 blocks memory in mice
Korb, E., Herre, M., Zucker-Scharff, I., Darnell, R. B., & Allis, C. D. (2015) · Nature Neuroscience · doi:10.1038/nn.4095 · Cited by 241 · cited 12×
“BET degraders (PROTACs) with their components and mechanism of action Compound BET inhibitor component Small-molecule component E3 ubiquitin ligase complex Reference ARV-771 JQ1 VHL ligand Von Hippel–Lindau-containing complex ( 111 ) ARV-825 OTX015 Thalidomide Cereblon E3 ubiquitin ligase complex ( 107 ) AT1 JQ1 VHL l…”
BackgroundInfluentialBET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism
Boehm, D., Calvanese, V., Dar, R. D., Xing, S., Schroeder, S., Martins, L., Aull, K., Li, P.-C., Planelles, V., Bradner, J. E., et al. (2013) · Cell Cycle · doi:10.4161/cc.23309 · Cited by 235
Stratikopoulos, E. E., Dendy, M., Szabolcs, M., Khaykin, A. J., Lefebvre, C., Zhou, M.-M., & Parsons, R. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.05.006 · Cited by 232
BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models
Kagoya, Y., Nakatsugawa, M., Yamashita, Y., Ochi, T., Guo, T., Anczurowski, M., Saso, K., Butler, M. O., Arrowsmith, C. H., & Hirano, N. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86437 · Cited by 214
Bhadury, J., Nilsson, L. M., Veppil Muralidharan, S., Green, L. C., Li, Z., Gesner, E. M., Hansen, H. C., Keller, U. B., McLure, K. G., & Nilsson, J. A. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1406722111 · Cited by 212
Brd4 links chromatin targeting to HPV transcriptional silencing
Wu, S.-Y., Lee, A.-Y., Hou, S. Y., Kemper, J. K., Erdjument-Bromage, H., Tempst, P., & Chiang, C.-M. (2006) · Genes & Development · doi:10.1101/gad.1448206 · Cited by 210
Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non–Small Cell Lung Cancer
Shimamura, T., Chen, Z., Soucheray, M., Carretero, J., Kikuchi, E., Tchaicha, J. H., Gao, Y., Cheng, K. A., Cohoon, T. J., Qi, J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3904 · Cited by 202 · cited 5×
“The presence of concomitant KRAS and LKB1 mutations in NSCLC (38, 46) and PIK3CA mutations in breast cancer (23) has been also associated with resistance to BET inhibitors.”
BackgroundInfluentialTargeted Degradation of BET Proteins in Triple-Negative Breast Cancer
Bai, L., Zhou, B., Yang, C.-Y., Ji, J., McEachern, D., Przybranowski, S., Jiang, H., Hu, J., Xu, F., Zhao, Y., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2622 · Cited by 199
Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer
Kurimchak, A. M., Shelton, C., Duncan, K. E., Johnson, K. J., Brown, J., O’Brien, S., Gabbasov, R., Fink, L. S., Li, Y., Lounsbury, N., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.06.091 · Cited by 198 · cited 1×
“Increased WNT signaling with β-catenin–mediated MYC expression in AML (88, 89), activation of the Hedgehog pathway with GLI2-mediated MYC expression in pancreatic cancer (90), hyperphosphorylation of BRD4 that leads to a bromodomain-independent binding to MED1 in triple-negative breast cancer (42), kinome reprogrammin…”
BackgroundAn epigenomic approach to therapy for tamoxifen-resistant breast cancer
Feng, Q., Zhang, Z., Shea, M. J., Creighton, C. J., Coarfa, C., Hilsenbeck, S. G., Lanz, R., He, B., Wang, L., Fu, X., et al. (2014) · Cell Research · doi:10.1038/cr.2014.71 · Cited by 194
Fiskus, W., Sharma, S., Qi, J., Valenta, J. A., Schaub, L. J., Shah, B., Peth, K., Portier, B. P., Rodriguez, M., Devaraj, S. G. T., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0770 · Cited by 190
Janouskova, H., El Tekle, G., Bellini, E., Udeshi, N. D., Rinaldi, A., Ulbricht, A., Bernasocchi, T., Civenni, G., Losa, M., Svinkina, T., et al. (2017) · Nature Medicine · doi:10.1038/nm.4372 · Cited by 186 · cited 1×
“Mutations of the SPOP gene, coding for a ubiquitin ligase adaptor protein, are associated with high sensitivity to BET inhibition in endometrial cancer cell lines but to resistance in prostate cancer cell lines due to an increased or decreased, respectively, degradation of the BET proteins in cases bearing SPOP mutati…”
BackgroundSelf-citationBolden, J. E., Tasdemir, N., Dow, L. E., van Es, J. H., Wilkinson, J. E., Zhao, Z., Clevers, H., & Lowe, S. W. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.08.025 · Cited by 185 · cited 1×
“Mice with reduced BRD4 levels present different reversible phenotypes with a decrease in the number of hematopoietic cells, skin hyperplasia with abnormal hair follicles, and disruption of the intestinal crypts with loss of the secretory cells and increased intestinal toxicity after exposure to radiation or doxorubici…”
BackgroundCeribelli, M., Kelly, P. N., Shaffer, A. L., Wright, G. W., Xiao, W., Yang, Y., Mathews Griner, L. A., Guha, R., Shinn, P., Keller, J. M., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411701111 · Cited by 185
Brd2 disruption in mice causes severe obesity without Type 2 diabetes
Wang, F., Liu, H., Blanton, W. P., Belkina, A., Lebrasseur, N. K., & Denis, G. V. (2010) · Biochemical Journal · doi:10.1042/bj20090928 · Cited by 185
Saenz, D. T., Fiskus, W., Qian, Y., Manshouri, T., Rajapakshe, K., Raina, K., Coleman, K. G., Crew, A. P., Shen, A., Mill, C. P., et al. (2017) · Leukemia · doi:10.1038/leu.2016.393 · Cited by 185
Sun, B., Fiskus, W., Qian, Y., Rajapakshe, K., Raina, K., Coleman, K. G., Crew, A. P., Shen, A., Saenz, D. T., Mill, C. P., et al. (2018) · Leukemia · doi:10.1038/leu.2017.207 · Cited by 178
Baratta, M. G., Schinzel, A. C., Zwang, Y., Bandopadhayay, P., Bowman-Colin, C., Kutt, J., Curtis, J., Piao, H., Wong, L. C., Kung, A. L., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1422165112 · Cited by 168
AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies
Rhyasen, G. W., Hattersley, M. M., Yao, Y., Dulak, A., Wang, W., Petteruti, P., Dale, I. L., Boiko, S., Cheung, T., Zhang, J., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0141 · Cited by 162 · cited 5×
“In preclinical experiments, OTX015 resulted in cell growth inhibition, cell-cycle arrest, and apoptosis in acute leukemia cell lines in which it also decreased the expression of BRD2, BRD4, and MYC and increased the expression of the MYCnegative regulator HEXIM1 ( 59 ).”
BackgroundInfluentialBerenguer‐Daizé, C., Astorgues‐Xerri, L., Odore, E., Cayol, M., Cvitkovic, E., Noel, K., Békradda, M., MacKenzie, S., Rezaï, K., Lokiec, F. M., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30256 · Cited by 161
Asangani, I. A., Wilder-Romans, K., Dommeti, V. L., Krishnamurthy, P. M., Apel, I. J., Escara-Wilke, J., Plymate, S. R., Navone, N. M., Wang, S., Feng, F. Y., et al. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0472 · Cited by 158
BET Bromodomain Inhibition Releases the Mediator Complex from Select cis-Regulatory Elements
Bhagwat, A. S., Roe, J.-S., Mok, B. Y. L., Hohmann, A. F., Shi, J., & Vakoc, C. R. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.03.054 · Cited by 158
Double bromodomain‐containing gene Brd2 is essential for embryonic development in mouse
Shang, E., Wang, X., Wen, D., Greenberg, D. A., & Wolgemuth, D. J. (2009) · Developmental Dynamics · doi:10.1002/dvdy.21911 · Cited by 156 · cited 1×
“The complete lack of either BRD2 or BRD4 is lethal (12–15) and, in general, low BET protein level is associated with reduced cell growth (12, 13).”
BackgroundDesign and characterization of bivalent BET inhibitors
Tanaka, M., Roberts, J. M., Seo, H.-S., Souza, A., Paulk, J., Scott, T. G., DeAngelo, S. L., Dhe-Paganon, S., & Bradner, J. E. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2209 · Cited by 156
Adeegbe, D. O., Liu, Y., Lizotte, P. H., Kamihara, Y., Aref, A. R., Almonte, C., Dries, R., Li, Y., Liu, S., Wang, X., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1020 · Cited by 149
You, J., Srinivasan, V., Denis, G. V., Harrington, W. J., Ballestas, M. E., Kaye, K. M., & Howley, P. M. (2006) · Journal of Virology · doi:10.1128/jvi.00502-06 · Cited by 146
Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer
Urbanucci, A., Barfeld, S. J., Kytölä, V., Itkonen, H. M., Coleman, I. M., Vodák, D., Sjöblom, L., Sheng, X., Tolonen, T. T., Minner, S. J. P., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.05.049 · Cited by 140 · cited 1×
“Gene expression signatures associated with sensitivity to BET inhibitors have been identified in different tumor models, but they still need to be further validated in the clinical context (36, 39, 41).”
BackgroundFiskus, W., Sharma, S., Qi, J., Shah, B., Devaraj, S. G. T., Leveque, C., Portier, B. P., Iyer, S., Bradner, J. E., & Bhalla, K. N. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0258 · Cited by 137
Structure-Guided Design of Potent Diazobenzene Inhibitors for the BET Bromodomains
Zhang, G., Plotnikov, A. N., Rusinova, E., Shen, T., Morohashi, K., Joshua, J., Zeng, L., Mujtaba, S., Ohlmeyer, M., & Zhou, M.-M. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401334s · Cited by 132
Baker, E. K., Taylor, S., Gupte, A., Sharp, P. P., Walia, M., Walsh, N. C., Zannettino, A. C. W., Chalk, A. M., Burns, C. J., & Walkley, C. R. (2015) · Scientific Reports · doi:10.1038/srep10120 · Cited by 130
Potent and selective bivalent inhibitors of BET bromodomains
Waring, M. J., Chen, H., Rabow, A. A., Walker, G., Bobby, R., Boiko, S., Bradbury, R. H., Callis, R., Clark, E., Dale, I., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2210 · Cited by 130
Jang, J. E., Eom, J.-I., Jeung, H.-K., Cheong, J.-W., Lee, J. Y., Kim, J. S., & Min, Y. H. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1903 · Cited by 128
Bui, M. H., Li, X., Albert, D. H., Li, L., Lam, L. T., Faivre, E. J., Warder, S. E., Huang, X., Wilcox, D. M., Donawho, C. K., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1793 · Cited by 127
Shahbazi, J., Liu, P. Y., Atmadibrata, B., Bradner, J. E., Marshall, G. M., Lock, R. B., & Liu, T. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1666 · Cited by 124
Zhao, X. L., Lwin, T., Zhang, X., Huang, A., Wang, J., Márquez, V. E., Chen‐Kiang, S., Dalton, W. S., Sotomayor, E., & Tao, J. (2013) · Leukemia · doi:10.1038/leu.2013.94 · Cited by 121
Gopalakrishnan, R., Matta, H., Tolani, B., Triche Jr, T., & Chaudhary, P. M. (2016) · Oncogene · doi:10.1038/onc.2015.245 · Cited by 112
Synergistic effect of JQ 1 and rapamycin for treatment of human osteosarcoma
Lee, D. H., Qi, J., Bradner, J. E., SAID, J. W., Doan, N., Forscher, C. A., Yang, H. H., & Koeffler, H. P. (2014) · International Journal of Cancer · doi:10.1002/ijc.29269 · Cited by 112
Moros, A., Rodríguez, V., Saborit-Villarroya, I., Montraveta, A., Balsas, P., Sandy, P., Martínez, A., Wiestner, A. U., Normant, E., Campo, E., et al. (2014) · Leukemia · doi:10.1038/leu.2014.106 · Cited by 108
Sun, B., Shah, B., Fiskus, W., Qi, J., Rajapakshe, K., Coarfa, C., Li, L., Devaraj, S. G. T., Sharma, S., Zhang, L., et al. (2015) · Blood · doi:10.1182/blood-2015-04-639542 · Cited by 104
The chromatin-targeting protein Brd2 is required for neural tube closure and embryogenesis
Gyuris, A., Donovan, D. J., Seymour, K. A., Lovasco, L. A., Smilowitz, N. R., Halperin, A. L. P., Klysik, J. E., & Freiman, R. N. (2009) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2009.03.005 · Cited by 102
Vázquez, R., Riveiro, M. E., Astorgues‐Xerri, L., Odore, E., Rezaï, K., Erba, E., Panini, N., Rinaldi, A., Kwee, I., Beltrame, L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13814 · Cited by 102
Self-citationThe EBNA1 Protein of Epstein-Barr Virus Functionally Interacts with Brd4
Lin, A., Wang, S., Nguyen, T., Shire, K., & Frappier, L. (2008) · Journal of Virology · doi:10.1128/jvi.01680-08 · Cited by 99
Emadali, A., Rousseaux, S., Costa, J. B., Rome, C., Duley, S., Hamaidia, S., Betton-Fraisse, P., Debernardi, A., Leroux, D., Bernay, B., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201202034 · Cited by 98
Kumar, K., Raza, S. S., Knab, L. M., Chow, C. R., Kwok, B., Bentrem, D. J., Popovic, R., Ebine, K., Licht, J. D., & Munshi, H. G. (2015) · Scientific Reports · doi:10.1038/srep09489 · Cited by 94
Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells
Borbély, G., Haldosén, L.-A., Dahlman‐Wright, K., & Zhao, C. (2015) · Oncotarget · doi:10.18632/oncotarget.5601 · Cited by 94
Bromodomain Protein Brd4 Plays a Key Role in Merkel Cell Polyomavirus DNA Replication
Wang, X., Li, J., Schowalter, R. M., Jiao, J., Buck, C. B., & You, J. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1003021 · Cited by 84
Wang, X., Helfer, C. M., Pancholi, N., Bradner, J. E., & You, J. (2013) · Journal of Virology · doi:10.1128/jvi.03068-12 · Cited by 84 · cited 1×
“76, 77, 79), human papillomavirus (HPV) 16 (80), human herpes simplex virus 1 and 2 (HSV-1 and HSV-2; ref.”
BackgroundSiu, K. T., Ramachandran, J., Yee, A. J., Eda, H., Santo, L., Panaroni, C., Mertz, J. A., Sims, R. J., Cooper, M. R., & Raje, N. S. (2016) · Leukemia · doi:10.1038/leu.2016.355 · Cited by 84 · cited 1×
“Increased WNT signaling with β-catenin–mediated MYC expression in AML (88, 89), activation of the Hedgehog pathway with GLI2-mediated MYC expression in pancreatic cancer (90), hyperphosphorylation of BRD4 that leads to a bromodomain-independent binding to MED1 in triple-negative breast cancer (42), kinome reprogrammin…”
BackgroundHeinemann, A., Cullinane, C., De Paoli-Iseppi, R., Wilmott, J. S., Gunatilake, D., Madore, J., Strbenac, D., Yang, J. Y., Gowrishankar, K., Tiffen, J. C., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4242 · Cited by 82
Bian, B., Bigonnet, M., Gayet, O., Loncle, C., Maignan, A., Gilabert, M., Moutardier, V., Garcia, S., Turrini, O., Delpéro, J., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201606975 · Cited by 76 · cited 1×
“Gene expression signatures associated with sensitivity to BET inhibitors have been identified in different tumor models, but they still need to be further validated in the clinical context (36, 39, 41).”
BackgroundHogg, S. J., Newbold, A., Vervoort, S. J., Cluse, L. A., Martin, B. P., Gregory, G. P., Lefebure, M., Vidacs, E., Tothill, R. W., Bradner, J. E., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0924 · Cited by 71 · cited 1×
“Increased WNT signaling with β-catenin–mediated MYC expression in AML (88, 89), activation of the Hedgehog pathway with GLI2-mediated MYC expression in pancreatic cancer (90), hyperphosphorylation of BRD4 that leads to a bromodomain-independent binding to MED1 in triple-negative breast cancer (42), kinome reprogrammin…”
BackgroundPeirs, S., Frismantas, V., Matthijssens, F., Loocke, W. V., Pieters, T., Vandamme, N., Lintermans, B., Dobay, M. P., Berx, G., Poppe, B. G., et al. (2017) · Leukemia · doi:10.1038/leu.2017.10 · Cited by 71
The BET inhibitor OTX015 reactivates latent HIV-1 through P-TEFb
Lu, P., Qu, X., Shen, Y., Jiang, Z., Wang, P., Zeng, H., Ji, H., Deng, J., Yang, X., Li, X., et al. (2016) · Scientific Reports · doi:10.1038/srep24100 · Cited by 70 · cited 1×
“Although this can be therapeutically exploited to eliminate latent viral infections (76, 77, 82), it advises for a close monitoring of patients with cancer receiving BET inhibitors for reactivation of viral infections.”
BackgroundZhao, Y., Liu, Q., Acharya, P., Stengel, K. R., Sheng, Q., Zhou, X., Kwak, H., Fischer, M. A., Bradner, J. E., Strickland, S. A., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.07.032 · Cited by 69
Lam, L. T., Lin, X., Faivre, E. J., Yang, Z., Huang, X., Wilcox, D. M., Bellin, R. J., Jin, S. S., Tahir, S. K., Mitten, M. J., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0459 · Cited by 69
Riveiro, M. E., Astorgues‐Xerri, L., Vázquez, R., Frapolli, R., Kwee, I., Rinaldi, A., Odore, E., Rezaï, K., Békradda, M., Inghirami, G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13181 · Cited by 68 · cited 5×
“The presence of concomitant KRAS and LKB1 mutations in NSCLC (38, 46) and PIK3CA mutations in breast cancer (23) has been also associated with resistance to BET inhibitors.”
BackgroundInfluentialSelf-citationFernandez, P., Scaffidi, P., Markert, E., Lee, J.-H., Rane, S., & Misteli, T. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.08.069 · Cited by 67 · cited 1×
“Finally, a tumor-suppressor role for BET proteins has also been reported in which their inhibition would result in a reduced immune surveillance (86) and reduced capacity of healthy cells to counteract the neoplastic transformation process (87).”
BackgroundFaivre, E. J., Wilcox, D. M., Li, X., Hessler, P., Torrent, M., He, W. A., Uziel, T., Albert, D. H., McDaniel, K. F., Kati, W. M., et al. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0221 · Cited by 65
Ember, S. W., Lambert, Q. T., Berndt, N., Gunawan, S., Ayaz, M., Tauro, M., Zhu, J., Cranfill, P. J., Greninger, P., Lynch, C. C., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0568-t · Cited by 65
Lin, X., Huang, X., Uziel, T., Hessler, P., Albert, D. H., Roberts-Rapp, L. A., McDaniel, K. F., Kati, W. M., & Shen, Y. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0475 · Cited by 63 · cited 4×
“In preclinical experiments, OTX015 resulted in cell growth inhibition, cell-cycle arrest, and apoptosis in acute leukemia cell lines in which it also decreased the expression of BRD2, BRD4, and MYC and increased the expression of the MYCnegative regulator HEXIM1 ( 59 ).”
BackgroundInfluentialAbramson, J. S., Blum, K. A., Flinn, I. W., Gutierrez, M., Goy, A., Maris, M., Cooper, M., O'Meara, M., Borger, D., Mertz, J., et al. (2015) · Blood · doi:10.1182/blood.v126.23.1491.1491 · Cited by 62 · cited 2×
“Thrombocytopenia, fatigue, gastrointestinal symptoms, and hyperbilirubinemia are among side effects also reported in patients treated with other BET inhibitors (62, 66, 67), although the results of these trials are currently preliminary and reported only in abstract form.”
BackgroundResultAutism-like syndrome is induced by pharmacological suppression of BET proteins in young mice
Sullivan, J. M., Badimon, A., Schaefer, U., Ayata, P., Gray, J., Chung, C.-W., von Schimmelmann, M., Zhang, F., Garton, N., Smithers, N., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20151271 · Cited by 61 · cited 1×
“Impaired long-term memory (84), reduced explorative motor activity, and heightened anxietylike behavior in the open field (85) have been observed in mice exposed to the BET inhibitors JQ1 (84) and I-BET858 (85), further suggesting that neurologic symptoms might be expected.”
BackgroundRVX-297- a novel BD2 selective inhibitor of BET bromodomains
Kharenko, O. A., Gesner, E. M., Patel, R. G., Norek, K., White, A., Fontano, E., Suto, R. K., Young, P. R., McLure, K. G., & Hansen, H. C. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.06.021 · Cited by 61
Siegel, M. B., Liu, S. Q., Davare, M. A., Spurgeon, S. E. F., Loriaux, M., Druker, B. J., Scott, E., & Tyner, J. W. (2015) · Oncotarget · doi:10.18632/oncotarget.4214 · Cited by 49
Shapiro, G. I., Dowlati, A., LoRusso, P. M., Eder, J. P., Anderson, A., Do, K. T., Kagey, M. H., Sirard, C. A., Bradner, J. E., & Landau, S. B. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-15-a49 · Cited by 47
Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma
Bernasconi, E., Gaudio, E., Lejeune, P., Tarantelli, C., Cascione, L., Kwee, I., Spriano, F., Rinaldi, A., Mensah, A. A., Chung, E., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14803 · Cited by 45 · cited 1×
“Signatures of exposure to BET inhibitors are relatively similar among different tumor types (31, 34, 35), but specific changes predominate in different cellular contexts in which BET inhibitors directly affect key tissue- or cancer-specific genes, mainly transcription factors (1, 4, 8, 28, 29, 31, 36–42).”
BackgroundSelf-citationO'Dwyer, P. J., Piha-Paul, S. A., French, C. A., Harward, S., Ferron‐Brady, G., Wu, Y., Barbash, O., Wyce, A., Annan, M., Horner, T., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-ct014 · Cited by 41
Keck, K. M., Moquin, S. A., He, A., Fernandez, S. G., Mohsen, J. J., Liu, S. M., Martinez, D. M., & Miranda, J. L. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.751644 · Cited by 38
Ren, K., Zhang, W. K., Chen, X., Ma, Y., Dai, Y., Fan, Y., Hou, Y., Tan, R. X., & Li, E. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005950 · Cited by 34
Massard, C., Soria, J., Stathis, A., Delord, J., Awada, A. H., Peters, S., Lewin, J. H., Bekradda, M., Rezaï, K., Zeng, Z., et al. (2016) · European Journal of Cancer · doi:10.1016/s0959-8049(16)32609-0 · Cited by 30 · cited 7×
“The presence of concomitant KRAS and LKB1 mutations in NSCLC (38, 46) and PIK3CA mutations in breast cancer (23) has been also associated with resistance to BET inhibitors.”
BackgroundInfluentialSelf-citationGaudio, E., Tarantelli, C., Ponzoni, M., Odore, E., Rezaï, K., Bernasconi, E., Cascione, L., Rinaldi, A., Stathis, A., Riveiro, M. E., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10983 · Cited by 28
Self-citationBET Inhibitors as Anticancer Agents: A Patent Review
Ali, I., Choi, G., & Lee, K. (2017) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892812666170808121228 · Cited by 28
Francisco, J. C., Dai, Q., Luo, Z., Wang, Y., Chong, R. H., Tan, Y., Xie, W., Lee, G. H., & Lin, C. (2017) · Molecular and Cellular Biology · doi:10.1128/mcb.00040-17 · Cited by 27
Boi, M., Todaro, M., Vurchio, V., Yang, S. N., Moon, J. H., Kwee, I., Rinaldi, A., Pan, H., Crescenzo, R., Cheng, M. M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12876 · Cited by 25
Self-citationLasorsa, E., Smonksey, M., Kirk, J. S., Rosario, S. R., Hernandez‐Ilizaliturri, F. J., & Ellis, L. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.352 · Cited by 20
Hottinger, A. F., Sanson, M., Moyal, E. C., Delord, J., Micheli, R. D., Rezaï, K., Leung, A. C. F., Perez, S., Békradda, M., Lachaux, N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.e14123 · Cited by 19
Postel-Vinay, S. C., Herbschleb, K. H., Massard, C., Woodcock, V. K., Ocker, M., Wilkinson, G., Walter, A. O., Ewerton, F., Poelman, M., Middleton, M. R., et al. (2016) · European Journal of Cancer · doi:10.1016/s0959-8049(16)32620-x · Cited by 17 · cited 1×
“On the other hand, the development of another BET inhibitor, BAY 1238097, was prematurely interrupted due to severe adverse events (mainly headaches) that occurred at doses below the predicted therapeutic dose (70).”
BackgroundTinsley, S., Meja, K. K., Shepherd, C., & Khwaja, A. (2015) · British Journal of Haematology · doi:10.1111/bjh.13283 · Cited by 15
Molecular genetics of aggressive B‐cell lymphoma
Dalla‐Favera, R. (2017) · Hematological Oncology · doi:10.1002/hon.2405 · Cited by 11 · cited 10×
“The activity of OTX015 in lymphoma cell lines is mainly cytostatic, with the exception of a subgroup of cell lines derived from non–germinal center B cell–like diffuse large B-cell lymphoma (DLBCL) bearing wild-type TP53 and mutations in MYD88 , CD79B , or CARD11 in which it induces apoptosis ( 36 ).”
ResultInfluentialTsujikawa, L. M., Norek, K., Calosing, C., Attwell, S., Gilham, D., Sharma, N., Tobin, J., Haager, M., Jahagirdar, R., Lakhotia, S., et al. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-lb-038 · Cited by 9
Tarantelli, C., Ekeh, H., Moscatello, C., Gaudio, E., Testa, A., Zucca, E., Stathis, A., Ciulli, A., & Bertoni, F. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-17-a179 · Cited by 7
Self-citationHottinger, A. F., Sanson, M., Moyal, E. C., Delord, J., Rezaï, K., Leung, A. C. F., Perez, S., Bekradda, M., Lachaux, N., & Chinot, O. L. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now188.196 · Cited by 4
Gaudio, E., Bernasconi, E., Tarantelli, C., Cascione, L., Kwee, I., Rinaldi, A., Ponzoni, M., Riveiro, M. E., Zucca, E., & Bertoni, F. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-15-b77 · Cited by 2
Self-citation
Cited by
Cellular senescence in ageing: from mechanisms to therapeutic opportunities
Di Micco, R., Krizhanovsky, V., Baker, D., & d’Adda di Fagagna, F. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-00314-w · Cited by 2,277
Targeting transcription factors in cancer — from undruggable to reality
Bushweller, J. H. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0196-7 · Cited by 919
Kidney fibrosis: from mechanisms to therapeutic medicines
Huang, R., Fu, P., & Ma, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01379-7 · Cited by 781
“BET proteins as epigenetic readers contain Brd2-4, and Brdt.(218) Increasing studies report that BET proteins could modulate kinds of cell functions such as pericyte/fibroblast activation, inflammation, cell growth, and differentiation.”
BackgroundTumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Wong, M., Mayoh, C., Lau, L. M. S., Khuong-Quang, D.-A., Pinese, M., Kumar, A., Barahona, P., Wilkie, E. E., Sullivan, P., Bowen-James, R., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1072-4 · Cited by 393
Metadata
- Authors
- Stathis, A., & Bertoni, F.
- Affiliations
- Istituto Oncologico della Svizzera Italiana (CH)
- Institute of Oncology Research (CH)
- Venue
- Cancer Discovery
- Published
- 2018-01-01
- Volume
- 8
- Issue
- 1
- Pages
- 24-36
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2779743226
- Cited by
- 463
- References
- 140
- Citations by year
- 2026: 21 · 2025: 45 · 2024: 60 · 2023: 67 · 2022: 60 · 2021: 70 · 2020: 81 · 2019: 40 · 2018: 18
- FWCI
- 3.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Oncoethix and Merck for the clinical trials (OTX015/MK-8628)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Keywords
- BET proteins, BET inhibitors, epigenetic reader protein, cancer epigenetics, hematologic malignancies, NUT carcinoma, combination therapy, adverse events, clinical trials, anticancer agents
- MeSH terms
- Carcinoma, Humans, Nuclear Proteins, Transcription Factors, Epigenesis, Genetic, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.